Form 4: Medpace CEO August J. Troendle Sells 100,000 Shares in Open Market Transactions

Medpace Holdings CEO August J. Troendle sold 100,000 shares of common stock in two separate transactions on March 4th and 5th, 2024, at weighted average prices of $403.12 and $402.70, respectively.

Summary

• August J. Troendle, CEO of Medpace Holdings, Inc., reported the sale of 100,000 shares of common stock.
• The sales occurred in two transactions on March 4th and March 5th, 2024.
• 50,000 shares were sold on March 4th at a weighted average price of $403.12, with individual transactions ranging from $400.52 to $408.21.
• Another 50,000 shares were sold on March 5th at a weighted average price of $402.70, with individual transactions ranging from $400.00 to $404.39.
• The transactions were executed pursuant to a limit order placed by Medpace Investors, LLC (MPI) during an open window period.
• Following the reported transactions, Troendle directly owns 806,643 shares and indirectly owns 4,933,019 shares through Medpace Investors, LLC.
• Troendle disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting insider trading activity. It doesn't inherently convey positive or negative sentiment, but the market's reaction to the sale could influence sentiment.

Industry Context

Insider sales are a common occurrence, and the market typically interprets them in the context of the individual's overall holdings and the company's performance. It's important to consider whether this sale is part of a pre-planned strategy or reflects a change in the executive's outlook on the company.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sale, potentially impacting the stock price.
• The sale could be perceived as a lack of confidence in the company's future prospects, although it could also be for personal financial planning reasons.

Key Dates